MX2023011870A - Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus. - Google Patents

Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.

Info

Publication number
MX2023011870A
MX2023011870A MX2023011870A MX2023011870A MX2023011870A MX 2023011870 A MX2023011870 A MX 2023011870A MX 2023011870 A MX2023011870 A MX 2023011870A MX 2023011870 A MX2023011870 A MX 2023011870A MX 2023011870 A MX2023011870 A MX 2023011870A
Authority
MX
Mexico
Prior art keywords
corona
viruses
antiviral agents
modified nucleosides
sars
Prior art date
Application number
MX2023011870A
Other languages
English (en)
Inventor
Raymond Schinazi
Franck Amblard
Hong Wang Zhang
Keivan Zandi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of MX2023011870A publication Critical patent/MX2023011870A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos, composiciones y métodos para prevenir, tratar o curar una infección por coronavirus en sujetos humanos u otros animales huéspedes. En una de las realizaciones, los compuestos se pueden usar para tratar una infección con un virus del síndrome respiratorio agudo grave, como, por ejemplo, coronavirus humano 229E, SARS, MERS, SARS-CoV-l (OC43) y SARS-CoV-2. En otra realización, los métodos se usan para tratar a un paciente infectado por un Flavivirus, Picornavirus, Togavirus o Bunyavirus.
MX2023011870A 2021-04-09 2022-04-11 Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus. MX2023011870A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163173354P 2021-04-09 2021-04-09
US202163175673P 2021-04-16 2021-04-16
US202163210246P 2021-06-14 2021-06-14
US202163288163P 2021-12-10 2021-12-10
US202263298836P 2022-01-12 2022-01-12
PCT/US2022/024289 WO2022217154A2 (en) 2021-04-09 2022-04-11 Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses

Publications (1)

Publication Number Publication Date
MX2023011870A true MX2023011870A (es) 2023-12-07

Family

ID=83546595

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2023011903A MX2023011903A (es) 2021-04-09 2022-04-11 Tionucleosidos como agentes antivirales.
MX2023011901A MX2023011901A (es) 2021-04-09 2022-04-11 Nucleosidos y analogos de nucleotidos como agentes antivirales.
MX2023011870A MX2023011870A (es) 2021-04-09 2022-04-11 Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2023011903A MX2023011903A (es) 2021-04-09 2022-04-11 Tionucleosidos como agentes antivirales.
MX2023011901A MX2023011901A (es) 2021-04-09 2022-04-11 Nucleosidos y analogos de nucleotidos como agentes antivirales.

Country Status (10)

Country Link
US (1) US20240216413A1 (es)
EP (3) EP4319762A2 (es)
JP (2) JP2024514825A (es)
KR (2) KR20230170015A (es)
AU (2) AU2022254108A1 (es)
BR (2) BR112023020600A2 (es)
CA (3) CA3214904A1 (es)
IL (2) IL307478A (es)
MX (3) MX2023011903A (es)
WO (3) WO2022217154A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
KR20220164784A (ko) 2020-04-06 2022-12-13 길리애드 사이언시즈, 인코포레이티드 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
TWI819321B (zh) 2020-06-24 2023-10-21 美商基利科學股份有限公司 1'-氰基核苷類似物及其用途
TW202228722A (zh) 2020-08-27 2022-08-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
EP4320128A1 (en) 2022-03-02 2024-02-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN116332996A (zh) * 2023-05-04 2023-06-27 南京颐媛生物医学研究院有限公司 抗冠状病毒化合物及其制备方法和应用
CN116284135A (zh) * 2023-05-04 2023-06-23 南京颐媛生物医学研究院有限公司 抗冠状病毒核苷类化合物的制备方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
US5128458A (en) * 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
AU2004274021B2 (en) * 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
RS52458B (en) * 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. E1 ENZYMING ENZYME INHIBITORS
US20110130440A1 (en) * 2008-03-26 2011-06-02 Alnylam Pharmaceuticals, Inc. Non-natural ribonucleotides, and methods of use thereof
WO2012142523A2 (en) * 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
WO2014197578A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv

Also Published As

Publication number Publication date
JP2024514825A (ja) 2024-04-03
CA3214726A1 (en) 2022-10-13
US20240216413A1 (en) 2024-07-04
WO2022217155A3 (en) 2022-11-17
BR112023020798A2 (pt) 2023-12-19
WO2022217154A2 (en) 2022-10-13
EP4319762A2 (en) 2024-02-14
KR20240006536A (ko) 2024-01-15
MX2023011903A (es) 2024-01-08
AU2022253068A1 (en) 2023-10-26
KR20230170015A (ko) 2023-12-18
CA3214918A1 (en) 2022-10-13
CA3214904A1 (en) 2022-10-13
AU2022254108A1 (en) 2023-10-26
IL307486A (en) 2023-12-01
WO2022217153A2 (en) 2022-10-13
WO2022217155A2 (en) 2022-10-13
JP2024513571A (ja) 2024-03-26
BR112023020600A2 (pt) 2023-12-12
EP4319764A2 (en) 2024-02-14
WO2022217153A3 (en) 2022-11-17
IL307478A (en) 2023-12-01
MX2023011901A (es) 2024-01-05
EP4319763A2 (en) 2024-02-14
WO2022217154A3 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2023011870A (es) Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.
MX2021014742A (es) Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
MX2022013270A (es) Aplicacion antiviral de analogo de nucleosido o formulacion combinada que contiene analogo de nucleosido.
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
TW200633995A (en) Andrographolide derivatives to treat viral infections
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
MX2009012299A (es) Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue.
ECSP077252A (es) Métodos para tratar la hepatitis C
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
MX2017013956A (es) Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
WO2007025043A3 (en) Seven-membered ring nucleosides
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
BR112022017243A2 (pt) Lactoferrina para uso oral com ação antiviral
BR112022022599A2 (pt) Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
MX2022010373A (es) Vacuna contra el virus de la peste porcina africana.
BRPI0513321A (pt) vìrus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BR112022023135A2 (pt) Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas
MX2022012576A (es) Inhibidores de axl para terapia antiviral.